These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 29908131)

  • 1. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
    Han SW; Won YW; Yi JH; Kim HJ
    Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Insufficiency in Concert with Renin-angiotensin-aldosterone Inhibition Is a Major Risk Factor for Hyperkalemia Associated with Low-dose Trimethoprim-sulfamethoxazole in Adults.
    Higashioka K; Niiro H; Yoshida K; Oryoji K; Kamada K; Mizuki S; Yokota E
    Intern Med; 2016; 55(5):467-71. PubMed ID: 26935365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Renin-Angiotensin System Blockers Increases Serum Potassium in Anuric Hemodialysis Patients.
    Movilli E; Camerini C; Gaggia P; Zubani R; Cancarini G
    Am J Nephrol; 2018; 48(2):79-86. PubMed ID: 30071530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Renin-Angiotensin Aldosterone System Inhibition on Serum Potassium Levels among Peritoneal Dialysis Patients.
    Ribeiro SC; Figueiredo AE; Barretti P; Pecoits-Filho R; de Moraes TP;
    Am J Nephrol; 2017; 46(2):150-155. PubMed ID: 28738355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?
    Silvariño R; Rios P; Baldovinos G; Chichet MA; Perg N; Sola L; Saona G; De Souza N; Lamadrid V; Gadola L
    Nephron; 2019; 143(2):100-107. PubMed ID: 31203280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations.
    Mitterbauer C; Heinze G; Kainz A; Kramar R; Hörl WH; Oberbauer R
    Nephrol Dial Transplant; 2008 May; 23(5):1742-6. PubMed ID: 18234845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Bolignano D; Palmer SC; Navaneethan SD; Strippoli GF
    Cochrane Database Syst Rev; 2014 Apr; (4):CD007004. PubMed ID: 24782282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID-19.
    Covino M; De Matteis G; Burzo ML; Santoro M; Fuorlo M; Sabia L; Sandroni C; Gasbarrini A; Franceschi F; Gambassi G;
    Intern Med J; 2020 Dec; 50(12):1483-1491. PubMed ID: 33022124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF.
    Beusekamp JC; Tromp J; van der Wal HH; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Metra M; Ng LL; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zwinderman AH; Rossignol P; Zannad F; Voors AA; van der Meer P
    Eur J Heart Fail; 2018 May; 20(5):923-930. PubMed ID: 29327797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. User of angiotensin-converting-enzyme inhibitor and/or angiotensin II receptor blocker might be associated with vascular calcification in predialysis chronic kidney disease patients: a retrospective single-center observational study : ACEI/ARB and vascular calcification.
    Takaori K; Iwatani H; Yamato M; Ito T
    BMC Nephrol; 2021 Jan; 22(1):7. PubMed ID: 33407242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy.
    Steely AM; Callas PW; Bertges DJ;
    J Vasc Surg; 2016 Mar; 63(3):715-21. PubMed ID: 26603543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD; Nigwekar SU; Sehgal AR; Strippoli GF
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007004. PubMed ID: 19588415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Acute Kidney Disease after an Episode of AKI: A Multicenter Prospective Cohort Study.
    Hines A; Li X; Ortiz-Soriano V; Saleh S; Litteral J; Ruiz-Conejo M; Wald R; Silver SA; Neyra JA
    Am J Nephrol; 2020; 51(4):266-275. PubMed ID: 32088714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker.
    Jun HR; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Yoon KH; Kim HS
    Cardiovasc Ther; 2021; 2021():5935149. PubMed ID: 33747123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
    Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J
    Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia due to coadministration of renin-angiotensin-system inhibitors and PPARγ agonists in uncomplicated diabetic patients.
    Raptis AE; Bacharaki D; Mazioti M; Marathias KP; Markakis KP; Raptis SA; Dimitriadis GD; Vlahakos DV
    Exp Clin Endocrinol Diabetes; 2012 Jul; 120(7):416-9. PubMed ID: 22441720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.